Filing overview and reporting period
The supplied filing is DelMar Pharmaceuticals, Inc.’s unaudited Form 10-Q for the three months ended September 30, 2016 (fiscal Q1 2017), filed November 10, 2016. This does not match the request metadata naming Tuhura Biosciences, Inc. or labeling the period 2016 Q1; verify the issuer and reporting period before relying on this summary.
DelMar is a clinical-stage cancer drug developer. Its lead candidate, VAL-083, was being developed for glioblastoma (GBM); the company also held certain commercial rights in China, where the drug was approved for chronic myelogenous leukemia and lung cancer. The filing reports no product revenue and says the company did not expect revenue in the near term.
Financial performance and position
- Revenue and margins: No revenue is reported; operating margins are therefore not meaningful.
- Loss: Net loss was $2.29 million, versus $1.62 million in the prior-year quarter. Loss available to common stockholders was $2.60 million, including a $307,298 Series B preferred dividend; basic loss per share was $0.23 versus $0.15.
- Expenses: Research and development was $732,729, up 21% year over year. General and administrative expense was $1.32 million, up 177%; the increase included substantial noncash share-based and equity costs, as well as Nasdaq listing and related professional fees.
- Cash flow: Operating activities used $1.61 million, compared with $1.40 million in the prior-year quarter. Financing activities provided $254,851, principally from warrant exercises; cash declined by $1.36 million to $4.80 million.
- Liquidity and liabilities: Working capital was $4.53 million, down from $5.69 million at June 30, 2016. Total assets were $5.05 million; current liabilities were $482,272, with a further $590,345 derivative liability. The balance sheet shows no conventional borrowings. Accumulated deficit was $34.84 million.
- Equity and dilution: Common shares outstanding were 11,381,997 at September 30. The company also had 902,238 Series B preferred shares, convertible into common stock, and 4,528,040 warrants and 856,250 options outstanding. Series B holders received 50,793 common shares as a quarterly dividend.
Changes and material developments
- Net loss increased by $668,951 year over year, despite lower fair-value losses on stock-option and derivative liabilities. Higher operating expenses, especially G&A, were the main reported cost increases.
- Cash fell from $6.16 million at June 30 to $4.80 million at September 30. The prior-year quarter included $2.45 million of financing proceeds, compared with $254,851 of net financing cash flow this quarter.
- DelMar said it raised approximately $7.2 million gross in a private placement and began Nasdaq trading under DMPI in July 2016. The filing attributes part of the quarter’s higher professional and listing costs to the uplisting and related registration work.
- The company completed its Phase I/II trial in refractory GBM and reported plans for a randomized pivotal Phase III trial, subject to FDA discussions and funding. Management described reported survival findings as preliminary and from a small, non-controlled study.
Outlook, risks, and unusual items
- Management estimated that available resources would fund operations beyond the next twelve months, but said additional funding would be needed to maintain development and general operations. It cautioned that financing might not be available on acceptable terms and that programs could be delayed, reduced, or discontinued.
- Starting the planned pivotal GBM Phase III trial would require additional funding. Other planned studies and collaborations were also contingent on funding, final agreements, or other conditions; the China partner was expected to fund specified China trials.
- VAL-083’s reported clinical activity and comparative survival data are not proof of efficacy: the filing emphasizes the small, uncontrolled nature of the study and says results require further investigation. The candidate was not approved outside China.
- Myelosuppression, particularly low platelet counts, was the principal dose-limiting toxicity described. The company also noted uncertainty in clinical development, regulatory outcomes, costs, and its ability to raise capital.
- Fair-value remeasurement of warrants and certain options affects reported losses and may cause volatility. The derivative liability was $590,345 at quarter-end; management identified valuation estimates as judgment-sensitive.
- Disclosure controls and procedures were reported as ineffective at period-end because of a material weakness previously described in the company’s 2016 Form 10-K. Management reported no material change in internal control over financial reporting during the quarter.
- Subsequent to quarter-end, the company reported $69,759 of warrant-exercise proceeds and conversion of 12,375 Series B shares into 30,938 common shares.
Investor verification priorities
- Confirm that this DelMar Pharmaceuticals filing—not a Tuhura Biosciences filing—is the intended document and verify the fiscal-period label.
- Review cash runway assumptions, planned financing needs, and the funding required for the pivotal Phase III trial.
- Check the final FDA-agreed trial design, enrollment plans, endpoints, and status of planned studies and partner agreements.
- Assess the underlying clinical evidence, including study size, comparator limitations, survival data, and reported safety findings.
- Reconcile dilution from preferred-stock conversion and dividends, warrants, options, and subsequent share issuances.
- Review remediation of the disclosed material weakness and the accounting assumptions behind derivative and share-based valuations.